Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real-life practice in Spain
- PMID: 11957763
Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real-life practice in Spain
Abstract
Objective: To investigate the influence of tamsulosin treatment on the severity of lower urinary tract symptoms (LUTS) and the impact on quality of life (QoL), including daily life activities and mental well being, in real life practice in Spain.
Methods: 2740 LUTS patients aged 45-75 years who visited a urologist office in Spain received tamsulosin 0.4 mg o.d.. At baseline, after 3 months and after 6 months of treatment a questionnaire was completed by the urologist and the patient. The urologist estimated some aspects of the patient's QoL related to his LUTS. The International Prostate Symptom Score (I-PSS) was used to assess the severity of LUTS, while the BPH-Specific Interference with Activities (BSIA) and the Total Mental Health Rate assessed the impact on daily life activities and psychological well being respectively.
Results: After 3 months of treatment tamsulosin significantly improved the mean total I-PSS compared to baseline. After 6 months, the mean total I-PSS was reduced by 11.0 points from a baseline score of 20.3 (> 50% reduction). Tamsulosin also significantly improved the mean total BSIA score and the mean Total Mental Health Rate. These observations were confirmed by the urologists' assessment of the patient's condition: an increase of more than 50% of patients with no or mild voiding and filling LUTS and an increase of 45% of patients with no or only a small interference of their LUTS with daily life activities. The withdrawal rate due to adverse reactions was 2.4%.
Conclusion: This study shows that tamsulosin improves LUTS and their impact on the patient's QoL and daily life activities, in the opinion of both the patients and the urologists.
Similar articles
-
Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.Int J Urol. 2006 Sep;13(9):1202-6. doi: 10.1111/j.1442-2042.2006.01594.x. Int J Urol. 2006. PMID: 16984553
-
Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.Arch Esp Urol. 2004 May;57(4):451-60. Arch Esp Urol. 2004. PMID: 15270291 Clinical Trial.
-
The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.BJU Int. 2007 Oct;100(4):853-7. doi: 10.1111/j.1464-410X.2007.07092.x. Epub 2007 Jul 23. BJU Int. 2007. PMID: 17662074
-
Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.Clin Ther. 2004 Nov;26(11):1701-13. doi: 10.1016/j.clinthera.2004.11.006. Clin Ther. 2004. PMID: 15639685 Review.
-
Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.Clin Ther. 2006 Jan;28(1):13-25. doi: 10.1016/j.clinthera.2006.01.004. Clin Ther. 2006. PMID: 16490576 Review.
Cited by
-
Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.Int Urol Nephrol. 2016 May;48(5):645-56. doi: 10.1007/s11255-015-1206-7. Epub 2016 Jan 25. Int Urol Nephrol. 2016. PMID: 26810324 Free PMC article.
-
Effects of alpha(1)-adrenoceptor antagonists on male sexual function.Drugs. 2006;66(3):287-301. doi: 10.2165/00003495-200666030-00002. Drugs. 2006. PMID: 16526818 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical